ZFHX4 mutation as a novel predictive biomarker for immune checkpoint blockade in non-small cell lung cancer.

被引：0
|
作者：
Shen, Peng
Zeng, Di
Lin, Zhenzi
Lin, Pei
Luo, Mingyang
Zhao, Lele
Chai, Huizi
Huang, Lingli
Xiao, Mingzhe
机构：
[1] Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China
[2] Southern Med Univ, Clin Med Sch 1, Guangzhou, Peoples R China
[3] Jiangsu Sim cere Diagnost Co Ltd, State Key Lab Translat Med & Innovat Drug Dev, Jiangsu Simcere Diagnost Co, Nanjing, Peoples R China
[4] Jiangsu Simcere Diagnost Co Ltd, Dept Med, Nanjing, Peoples R China
[5] Jiangsu Simcere Diagnost Co Ltd, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20535
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Immune checkpoint inhibitors in non-small cell lung cancer: is simultaneous blockade better?
    Eubanks, Jennifer T.
    Ramalingam, Suresh S.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S532 - S535
  • [22] Clinical predictive markers of response to immune checkpoint inhibitor therapy in advanced non-small cell lung cancer.
    Rhone, Raena
    Dumais, Katerine
    Powery, Herman W.
    Gentile, Frank
    Raez, Luis E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer
    Gao, Ruyun
    Lou, Ning
    Li, Lin
    Xie, Tongji
    Xing, Puyuan
    Tang, Le
    Yao, Jiarui
    Han, Xiaohong
    Shi, Yuankai
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [24] PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
    Zhou, Huaqiang
    Liu, Jiaqing
    Zhang, Yaxiong
    Huang, Yan
    Shen, Jiayi
    Yang, Yunpeng
    Fang, Wenfeng
    Zhang, Li
    NPJ PRECISION ONCOLOGY, 2020, 4 (01)
  • [25] PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
    Huaqiang Zhou
    Jiaqing Liu
    Yaxiong Zhang
    Yan Huang
    Jiayi Shen
    Yunpeng Yang
    Wenfeng Fang
    Li Zhang
    npj Precision Oncology, 4
  • [26] The effect and safety of an immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
    Watanabe, Hiromi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kudo, Kenichiro
    Minami, Daisuke
    Murakami, Etsuko
    Ochi, Nobuaki
    Ninomiya, Takashi
    Harada, Daijiro
    Yasugi, Masayuki
    Ichihara, Eiki
    Ohashi, Kadoaki
    Fujiwara, Keiichi
    Hotta, Katsuyuki
    Tabata, Masahiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Robust prediction of immune checkpoint inhibition therapy for non-small cell lung cancer.
    Zhang, Yiqun
    Zhao, Guodong
    He, Ning
    Wang, Lingyu
    Wang, Jianfei
    Jin, Ge
    Lin, Rongbo
    Yang, Yadong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Anagnostou, Valsamo
    Forde, Patrick M.
    White, James R.
    Niknafs, Noushin
    Hruban, Carolyn
    Naidoo, Jarushka
    Marrone, Kristen
    Sivakumar, I. K. Ashok
    Bruhm, Daniel C.
    Rosner, Samuel
    Phallen, Jillian
    Leal, Alessandro
    Adleff, Vilmos
    Smith, Kellie N.
    Cottrell, Tricia R.
    Rhymee, Lamia
    Palsgrove, Doreen N.
    Hann, Christine L.
    Levy, Benjamin
    Feliciano, Josephine
    Georgiades, Christos
    Verde, Franco
    Illei, Peter
    Li, Qing Kay
    Gabrielson, Edward
    Brock, Malcolm V.
    Isbell, James M.
    Sauter, Jennifer L.
    Taube, Janis
    Scharpf, Robert B.
    Karchin, Rachel
    Pardoll, Drew M.
    Chaft, Jamie E.
    Hellmann, Matthew D.
    Brahmer, Julie R.
    Velculescu, Victor E.
    CANCER RESEARCH, 2019, 79 (06) : 1214 - 1225
  • [29] Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors
    Takeuchi, Eiji
    Kondo, Kensuke
    Okano, Yoshio
    Ichihara, Seiya
    Kunishige, Michihiro
    Kadota, Naoki
    Machida, Hisanori
    Hatakeyama, Nobuo
    Naruse, Keishi
    Ogino, Hirokazu
    Nokihara, Hiroshi
    Shinohara, Tsutomu
    Nishioka, Yasuhiko
    THORACIC CANCER, 2023, 14 (30) : 3042 - 3050
  • [30] Intratumoral heterogeneity as a predictive biomarker in immunotherapy for advanced non-small cell lung cancer.
    Xiao, HaiPing
    Chen, Kai
    Zheng, Yating
    Huang, Mengli
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345